 Amelioration of mouse models of many diseases has been shown to occur by deletion of the NLRP3 inflammasome, including gout, type 2 diabetes, multiple sclerosis, Alzheimer's disease, and atherosclerosis.The compound β-Hydroxybutyrate has been shown to block NLRP3 activation, and thus may be of benefit for many of these diseases.Deregulation of NALP3 has been connected with carcinogenesis.